Removing Regulatory Hurdles for Continuous Pharmaceutical Manufacturing
ISPE
JULY 5, 2023
This article discusses how US regulators addressed the regulatory hurdles related to CM to broaden its adoption through engagement, regulatory science, guidance, and international harmonization. 13 An FDA-authored paper indicating support for the implementation of CM using science- and risk-based approaches followed soon thereafter.
52 
Let's personalize your content